Solvonis Therapeutics (LSE:SVNS) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Solvonis Therapeutics EBITDA Margin %?

Solvonis Therapeutics LSE:SVNS +5.00% EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 3,028 Industrial Products companies, Solvonis Therapeutics ranks worse than 33025.07% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Solvonis Therapeutics's EBITDA for the six months ended in Dec. 2025 was £-4.12 Mil. Solvonis Therapeutics's Revenue for the six months ended in Dec. 2025 was £0.00 Mil. Therefore, Solvonis Therapeutics's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Solvonis Therapeutics  (LSE:SVNS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Solvonis Therapeutics EBITDA Margin % Related Terms

Solvonis Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Solvonis Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics EBITDA Margin % Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial -64.42 -477.49 -500.51 0.00 0.00

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -550.14 0.00 0.00 0.00 0.00

LSE:SVNS vs GEV, ETN, PH: EBITDA Margin % Comparison

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solvonis Therapeutics EBITDA Margin % vs Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's EBITDA Margin % falls into.


Solvonis Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Solvonis Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.74/0
= %

Solvonis Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-4.123/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Solvonis Therapeutics (LSE:SVNS) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #999999 out of 3028 companies in the Industrial Products industry.
Is Solvonis Therapeutics' EBITDA Margin % too high?
Solvonis Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Solvonis Therapeutics ranks #999999 out of 3028 companies in the Industrial Products industry, which is in the bottom quartile relative to peers.
How does Solvonis Therapeutics' EBITDA Margin % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Solvonis Therapeutics ranks #999999 out of 3028 companies for EBITDA Margin %. This places Solvonis Therapeutics in the lower half of its industry. The industry median EBITDA Margin % is 9.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for an Industrial Products company?
The median EBITDA Margin % among Industrial Products companies is 9.45, based on 3,028 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Solvonis Therapeutics and its competitors. For the Industrial Products industry, the median EBITDA Margin % is 9.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solvonis Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Solvonis Therapeutics (LSE:SVNS) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.00 — trading 91.6% below its estimated fair value. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Solvonis Therapeutics (LSE:SVNS), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solvonis Therapeutics Business Description

Other Exchanges J4I:Germany
Address Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.